@article {10.3844/ajbbsp.2021.205.207,
article_type = {journal},
title = {Sofosbuvir May be a Potential Anti-SARS-CoV-2 RdRp Drug},
author = {Ibrahim, Mohamed Nabil and Elfiky, Abdo Abdellah},
volume = {17},
number = {2},
year = {2021},
month = {May},
pages = {205-207},
doi = {10.3844/ajbbsp.2021.205.207},
url = {https://thescipub.com/abstract/ajbbsp.2021.205.207},
abstract = {The Coronavirus Diseases 2019 (COVID-19) seriously affecting human health all over the world. More than 107 M people are reported positive for SARS-CoV-2, the virus causing COVID-19 pneumonia, from which +2.3 M died. Nucleotide Inhibitors (NI) have promising results in terms of its efficacy against different viral polymerases, including the Hepatitis C Virus (HCV) Non-Structural Protein 5 B (NS5B) RNA dependent RNA polymerase (RdRp) 1. Thus, the non-structural protein 12 (nsp12) RdRp of the human coronavirus represents an attractive target to develop a possible therapeutic agent. Sofosbuvir proved itself as a potential anti-SARS-CoV-2 RdRp and could inhibit viral replication and infection propagation.},
journal = {American Journal of Biochemistry and Biotechnology},
publisher = {Science Publications}
}